Group 1 - The core point of the news is that He Yuan Bio experienced a decline in stock price by 3.29% on November 17, with a trading volume of 531 million yuan [1][2] - On the same day, He Yuan Bio had a financing buy-in amount of 54.18 million yuan and a net financing buy-in of 6.57 million yuan, with a total financing and securities balance of 375 million yuan as of November 17 [1][2] - The company reported a significant increase in the number of shareholders, reaching 47,100, which is an increase of 84,075% compared to the previous period [2] Group 2 - He Yuan Bio's main business involves the research, production, and sales of products using rice endosperm cell recombinant protein expression technology, with recombinant human albumin accounting for 75.44% of its revenue [2] - For the period from January to September 2025, He Yuan Bio achieved a revenue of 19.66 million yuan, representing a year-on-year decrease of 8.51%, while the net profit attributable to the parent company was -121 million yuan, also a decrease of 8.44% year-on-year [2]
禾元生物11月17日获融资买入5418.10万元，融资余额3.75亿元